

4-24-2018

Epigenetic Regulation of Tumor Suppressors by Helicobacter pylori Enhances EBV-Induced Proliferation of Gastric Epithelial Cells

Saurabh Pandey
University of Pennsylvania

Hem Chandra Jha
University of Pennsylvania; Indian Institute of Technology

Sanket Kumar Shukla
Thomas Jefferson University; University of Pennsylvania, Sanket.Shukla@jefferson.edu

Meghan K. Shirley
University of Pennsylvania; University College London

Erle S. Robertson
University of Pennsylvania

[Let us know how access to this document benefits you](#)

Follow this and additional works at: <https://jdc.jefferson.edu/medfp>

 Part of the [Medical Microbiology Commons](#)

Recommended Citation

Pandey, Saurabh; Jha, Hem Chandra; Shukla, Sanket Kumar; Shirley, Meghan K.; and Robertson, Erle S., "Epigenetic Regulation of Tumor Suppressors by Helicobacter pylori Enhances EBV-Induced Proliferation of Gastric Epithelial Cells" (2018). *Department of Medicine Faculty Papers*. Paper 235.
<https://jdc.jefferson.edu/medfp/235>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Medicine Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.



Epigenetic Regulation of Tumor Suppressors by *Helicobacter pylori* Enhances EBV-Induced Proliferation of Gastric Epithelial Cells

Saurabh Pandey,^a Hem Chandra Jha,^{a*} Sanket Kumar Shukla,^{a*} Meghan K. Shirley,^{a*} Erle S. Robertson^a

^aDepartments of Otorhinolaryngology-Head and Neck Surgery, and Microbiology, the Tumor Virology Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA

ABSTRACT *Helicobacter pylori* and Epstein-Barr virus (EBV) are two well-known contributors to cancer and can establish lifelong persistent infection in the host. This leads to chronic inflammation, which also contributes to development of cancer. Association with *H. pylori* increases the risk of gastric carcinoma, and coexistence with EBV enhances proliferation of infected cells. Further, *H. pylori*-EBV coinfection causes chronic inflammation in pediatric patients. We have established an *H. pylori*-EBV coinfection model system using human gastric epithelial cells. We showed that *H. pylori* infection can increase the oncogenic phenotype of EBV-infected cells and that the cytotoxin-associated gene (CagA) protein encoded by *H. pylori* stimulated EBV-mediated cell proliferation in this coinfection model system. This led to increased expression of DNA methyl transferases (DNMTs), which reprogrammed cellular transcriptional profiles, including those of tumor suppressor genes (TSGs), through hypermethylation. These findings provide new insights into a molecular mechanism whereby cooperativity between two oncogenic agents leads to enhanced oncogenic activity of gastric cancer cells.

IMPORTANCE We have studied the cooperativity between *H. pylori* and EBV, two known oncogenic agents. This led to an enhanced oncogenic phenotype in gastric epithelial cells. We now demonstrate that EBV-driven epigenetic modifications are enhanced in the presence of *H. pylori*, more specifically, in the presence of its CagA secretory antigen. This results in increased proliferation of the infected gastric cells. Our findings now elucidate a molecular mechanism whereby expression of cellular DNA methyl transferases is induced influencing infection by EBV. Hypermethylation of the regulatory genomic regions of tumor suppressor genes results in their silencing. This drastically affects the expression of cell cycle, apoptosis, and DNA repair genes, which dysregulates their associated processes, and promotion of the oncogenic phenotype.

KEYWORDS Epstein-Barr virus, *Helicobacter pylori*, epigenetics, transformation

Helicobacter pylori functions together with Epstein-Barr virus (EBV) as a group 1 carcinogen which contributes to the development of gastric cancer (GC) (1, 2). EBV is associated with several types of lymphoid and epithelial cancers, including GC (3–5). Previous studies also suggested that EBV can transform primary gastric epithelial cells *in vitro* (6). Therefore, EBV is likely not a passive carrier but an active oncogenic virus contributing to early events in development of GC (4, 7). More importantly, EBV-positive GC harbors EBV DNA in a uniform, monoclonal presence in all carcinoma cells (7, 8), and patients show high antibody titers against EBV prior to diagnosis (9). In a study with pediatric patients, coinfection with *H. pylori* and EBV caused severe gastritis and chronic inflammation compared to individual infection of the respective pathogens (10). Fur-

Received 23 March 2018 Accepted 27 March 2018 Published 24 April 2018

Citation Pandey S, Jha HC, Shukla SK, Shirley MK, Robertson ES. 2018. Epigenetic regulation of tumor suppressors by *Helicobacter pylori* enhances EBV-induced proliferation of gastric epithelial cells. *mBio* 9:e00649-18. <https://doi.org/10.1128/mBio.00649-18>.

Editor Terence S. Dermody, University of Pittsburgh School of Medicine

Copyright © 2018 Pandey et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Erle S. Robertson, erle@upenn.edu.

* Present address: Hem Chandra Jha, Center for Biosciences and Bioengineering, Indian Institute of Technology, Indore, India; Sanket Kumar Shukla, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA; Meghan K. Shirley, Institute of Child Health, University College London, London, England.

This article is a direct contribution from a Fellow of the American Academy of Microbiology. Solicited external reviewers: Blossom Damania, UNC Chapel Hill; Bala Chandran, University of South Florida; Shou-Jiang Gao, USC Keck School of Medicine.

ther, many reports have highlighted the significance of EBV and *H. pylori* in GC. However, not much has been done to investigate the molecular mechanism linked to coinfection of these agents or the degree or extent of associated pathologies, in this case, those represented by gastric cancer.

Pathogens coexisting with host cells can act as effectors of gene regulation through epigenetic modifications. This impacts the overall etiology and pathogenesis associated with the respective disease. For example, the periodontal bacterium *Porphyromonas gingivalis* can induce EBV reactivation through chromatin modification (11). This bacterium-virus synergy affects EBV-associated periodontal pathology (11). Furthermore, *H. pylori* and EBV have also been shown to impact epigenetic modifications of host cells (12, 13). This relationship, which exists within the microbial milieu and modulates host gene expression, can directly impact disease pathology.

We investigated the molecular mechanism to elucidate the underlying strategy, which involves cooperation of *H. pylori* in EBV-driven proliferation of gastric epithelial cells. We developed an *H. pylori* and EBV coinfection model by the use of NCI-N87 human gastric epithelial cells, which is an excellent system mimicking human gastric epithelium (14). We demonstrated that the cytotoxin-associated gene (CagA) protein encoded by *H. pylori* promoted EBV-mediated proliferation of infected cells in our model system. Furthermore, we determined that the epigenetic status of EBV-infected cells was modulated as a consequence of *H. pylori* coinfection. This reprogramming resulted in upregulation of DNA methyl transferases (DNMTs), known epigenetic modifiers, leading to promoter methylation of CpG-rich islands of cell cycle-, DNA repair-, and apoptosis-related tumor suppressor genes (TSGs). Hypermethylation of the regulatory regions of these TSGs resulted in changes in cellular transcription profiles and the microenvironment that favored oncogenesis.

RESULTS

***H. pylori* enhances EBV infection and virion production in human gastric epithelial cells.** The interplay between EBV and *H. pylori* and the downstream implications of that interplay were investigated by establishing an *in vitro* coinfection system using the NCI-N87 gastric cell line, which mimics cells of the gastric epithelium (14, 15). *H. pylori* and EBV cultures were established as described in Materials and Methods. As expected, *H. pylori* showed regular spiral morphology by Gram stain as described earlier (16) (see Fig. S1 in the supplemental material). We studied two possible approaches for construction of a system using EBV and *H. pylori* coinfection. The first approach was that of simultaneous infection, where *H. pylori* and EBV were incubated simultaneously with the cells (infection I), and the second was that of sequential infection, where the gastric epithelial cells were first incubated with *H. pylori* and then subjected to infection with EBV (infection II). The results showed that sequential infection of the culture with EBV following preincubation with *H. pylori* was the more effective approach, as it provided to the cells an opportunity to establish and maintain a microenvironment suitable for more-efficient viral infection (Fig. 1A). After infection, fluorescent microscopic imaging and densitometric quantitation were performed at specific time points prior to exposure of the cells with *H. pylori*. This method showed greater efficiency of infection than simultaneous and control infections as determined by examination of green fluorescent protein (GFP) signals (Fig. 1B and C). A significant increase in fluorescence at 5 days postinfection (dpi) as determined by densitometric analysis (Fig. 1D and E) was also observed. Thereafter, the infection II setup was used in all of the experiments that followed.

The relative viral copy numbers measured at 2 and 5 dpi for both cell-associated and extracellular virion particles were significantly and reproducibly higher during coinfection than during EBV infection alone (Fig. 1F and G). Similarly, relatively higher viral loads were observed when the cells were exposed to *H. pylori* culture supernatant, which would have contained secreted factors (Fig. S2). The level of relative density (RD) of the GFP signal clearly showed a strong increase in efficiency of viral infection by 5




FIG 1 *H. pylori* increases the efficiency of EBV infection and virion production in gastric cells. (A) NCI-N87 cells were infected with GFP-EBV with and without coinfection with *H. pylori*. The infection scheme is depicted in the diagram. NCI-N87 cells were cultured in 6-well plates, and exposure to *H. pylori* was performed using a transwell filter. Secretory antigens cross the transwell to which NCI-N87 cells are exposed. EBV, being smaller than the membrane cutoff pore size, has access to the whole volume. (B) Infection I (simultaneous infection of EBV and *H. pylori*). (C) Infection II. *H. pylori* and EBV were infected in sequence, and preinfection of *H. pylori* was done for 48 h. Infection performed without *H. pylori* (i.e., infection using only EBV) and mock infection (i.e., no infection [mock]) were used as controls. The experiment was performed three times, and images from a representative experiment are presented. (D and E) The fluorescent micrograph results were quantified using densitometric analyses, and data from the (D) simultaneous infections and (E) sequential infections are presented as relative density (RD) values. (F and G) Relative EBV-GFP DNA copy numbers were quantified as a measure of EBV load using (F) intracellular and (G) extracellular released EBV in the culture and real-time qPCR.

to 7 dpi (Fig. S2A and B). Interestingly, the levels of intracellular and extracellular virions also increased in the cells exposed to *H. pylori* supernatant (Fig. S2C and D).

EBV can establish two distinct modes of postinfection replication, namely, latent replication and lytic replication. Furthermore, latent infection promotes cellular oncogenesis. However, recent studies showed that lytic activation is also a major contributor to the oncogenic process (17). To identify the mode of viral replication, we examined the expression status of two EBV genes: genes EBNA1 (latent infection) and BZLF1 (lytic infection) (Fig. 2). The results showed that the expression levels of both EBNA1 and BZLF1 were enhanced during coinfection compared to the results seen with infection with EBV alone as determined by immunofluorescence (Fig. 2A). The transcript levels of EBNA1 were also increased (Fig. 2B). Notably, we observed a significant increase in the levels of the immediate early transcript BZLF1 at 5 dpi, indicating a significant burst of lytic replication, early during infection. Moreover, when cells were exposed to *H. pylori* prior to EBV infection, the expression levels of BZLF1 increased from 15-fold to 24-fold, which represents a greater increase in viral lytic activity (Fig. 2C). These data validated our fluorescence data determined using the anti-BZLF1 monoclonal antibody (compare the panels at the right side in Fig. 2A and C). Similar findings were obtained when cells were preincubated with *H. pylori* culture supernatant (Fig. S3C). We found that the expression levels of the latent EBNA1 gene and the immediate early BZLF1 gene carried by EBV were upregulated as seen by immunofluorescence upon preincubation with *H. pylori* culture supernatant followed by EBV infection. Furthermore, an increase in transcript levels was also seen for the gp350 lytic gene (Fig. S3D). These results demonstrated that factors secreted by *H. pylori* are likely important in driving upregulation of these virus-carried genes.

Exposure to *H. pylori* resulted in increased production of infectious virions in EBV-infected gastric epithelial cells. To further support our results described above, which showed augmentation of lytic EBV infection when cells were exposed to *H. pylori* prior to EBV infection, we evaluated the viability of GFP-EBV progeny produced after infection. Progeny of GFP-EBV were collected, filtered, and used to infect a fresh culture of NCI-N87 gastric cells. After infection, the level of GFP expression in the newly infected cells was measured at 1, 2, and 5 dpi. As expected, the relative GFP density was observed to be higher when infection was performed using progeny EBV collected as described above from the supernatant obtained from coinfecting NCI-N87 cells (Fig. 3A). Interestingly, the fluorescence intensity doubled after 2 dpi in the case of cells infected with supernatant from the cultures coinfecting with *H. pylori* and EBV (Fig. 3A). Furthermore, the virus produced from the coinfecting gastric cells showed greater lytic burst and, within 48 h postinfection, showed GFP signals that were more than two times higher in terms of relative density than those seen with the virions produced from gastric cells infected with EBV alone (Fig. 3B). Nevertheless, the changes in the levels of GFP signals seen at 5 dpi were not as dramatic, but the signals from the virions obtained from coinfecting gastric epithelial cells were consistently higher (Fig. 3B). These results showed that the ability to infect new gastric cells was enhanced in EBV produced from gastric cells that had previously been exposed to *H. pylori*. Interestingly, similar observations were recorded when, instead of *H. pylori* bacteria, *H. pylori* supernatant or cell-free culture medium was used; the results showed enhanced levels of GFP signals, which indicated infection of NCI-N87 cells (Fig. S4A and B). To determine if the changes in the levels of the signals were due to passive GFP transfer, we incubated NCI-N87 cells as described above with supernatant obtained from GFP-transfected HEK-293 cells as a control. No passive transfer of GFP was seen in the NCI-N87 cells, indicating that the levels of GFP signals measured in the experiments described above were not due to passive transfer (Fig. S4C).

Acyclovir inhibits efficient production of EBV progeny from gastric epithelial cells coinfecting with *H. pylori*. In our studies described above, we found that the density of fluorescence was significantly higher in the coinfection model than in the model using EBV infection alone. Using acyclovir [ACV; 9-(2-hydroxyethoxy methyl) guanine], it was observed that there was an almost complete shutdown of signals




FIG 2 *H. pylori*-EBV coinfection results in upregulation of EBV latent and lytic genes. (A) NCI-N87 cells were coinfecting with *H. pylori*-EBV-GFP along with the control. Cells were examined for the expression of latent and lytic marker genes (EBNA1 and BZLF1, respectively) at different time points (1, 2, and 5 dpi) using fluorescence microscopy. DIC, differential interference contrast; DAPI, 4',6-diamidino-2-phenylindole. (B to E) The expression profiles of EBNA1 (B), BZLF1 (C), EBNA3C (D), and gp350 (E) were analyzed at the transcript level using RT-qPCR.

indicating viral infection by 5 days in the infections performed with EBV alone (Fig. 3C and D). However, in coinfection experiments performed in the presence of the antiviral drug acyclovir, we observed a slightly higher level of signal which indicated that there was a low level of viral infection, although this signal was about 50% lower than that seen without the drug (Fig. 3; compare panels C and E with panels D and F). This efficiency indicated that coinfection of *H. pylori* and EBV increased the efficiency of infection by the virions produced even when replication was blocked by the inhibitor (Fig. 3D and F).




FIG 3 *H. pylori*-EBV coinfection results in an increase of viral infectivity and is controlled by the antiviral drug ACV. (A) Infectious virions produced in the first coinfection and in the control experiment were collected, and a fresh infection was set up. Then, levels of viral load and infectivity were estimated by the use of a microscope at different time points. Data from one representative experiment are representative of results from experiments performed in triplicate. (B) Fluorescent intensity was quantitated for the triplicate experiments and normalized against the mock infection data, and relative expression density data are plotted. (C and D) Microscopic analysis of GFP expression was performed in the absence (C) and presence (D) of *H. pylori* (HP) by comparing the effects of 25 μ M ACV in both groups along with a no-ACV control. The experiment was performed in triplicate, and data from a representative experiment are presented. (E and F) Relative density (RD) data corresponding to GFP expression as a measure of EBV abundance in the absence (E) and presence (F) of *H. pylori* were plotted after quantitation of the fluorescent intensity measured in all three experiments.

CagA encoded by WT *H. pylori* is important for enhanced EBV infection of gastric epithelial cells. Using the coinfection model described above, an *H. pylori* CagA-deleted mutant [(CagA⁻)] was evaluated for its ability to enhance EBV infection of gastric cells (18). The progeny EBV was quantified in comparison to the results seen with the isogenic wild-type (WT) *H. pylori* [*H. pylori*(WT)] strain. Notably, our results showed that there was a significant drop in efficiency of infection in the absence of the CagA gene (Fig. 4A). At 2 dpi, there was little or no difference observed between EBV coinfecting with wild-type (WT) *H. pylori* and EBV coinfecting with *H. pylori*(CagA⁻). At 5 dpi, however, there was an approximately 40% drop in signal (Fig. 4A). The quanti-




FIG 4 *H. pylori*-encoded CagA enhances the efficiency of EBV infection in gastric epithelial cells. (A) Fluorescence and phase-contrast images were captured at different time points in coinfection of EBV-GFP along with *H. pylori* wild-type and CagA mutant strains. The experiment was performed in triplicate, and data from a representative experiment are presented. (B) Relative fluorescence density data were plotted after quantification of the results from all three experiments.

tation of these results indicated that CagA is an important contributor to the increased production of EBV virions and to the potency of its infection in the context of coinfection with *H. pylori* (Fig. 4B). The dramatic drop in signal seen with the *H. pylori* CagA mutant compared to WT *H. pylori* at 5 dpi was, however, greater than that seen with EBV alone (Fig. 4B). Further studies performed using the supernatant of NCI-N87 cells after infection with EBV alone, coinfection with *H. pylori*(WT) and EBV, and coinfection with *H. pylori*(CagA⁻) and EBV to infect fresh gastric NCI-N87 cells showed a dramatic drop in infection potency at 2 dpi, with some recovery at 5 dpi (Fig. S5A and B). The GFP signal for infection was also clearly lower with the CagA mutant culture supernatant from infected NCI-N87 cells at 5 dpi, although less than the relative density of the signals at 2 dpi (Fig. S5B). Interestingly, the results seen after blocking early replication using acyclovir did not show any major difference in the levels of the resulting signals in comparisons of the results of *H. pylori*(WT) coinfection to the results of *H. pylori*(CagA⁻) coinfection of NCI-N87 cells with EBV. This indicated that the levels of replication of the virions in the two coinfections in the presence of acyclovir were inhibited to similar extents (Fig. S5; compare panels C and E with panels D and F).

***H. pylori*-EBV coinfection led to aberrant methylation of genes regulating major cellular processes.** In previous studies, we showed that EBV infection of primary B cells leading to transformation relied on dysregulation of the cellular methylation program that resulted from hijacking major cellular epigenetic modifiers (19, 20). DNMTs regulate cellular epigenetic methylation patterns, including promoter hypermethylation of TSGs and oncogenic hypomethylation, in EBV-associated cancers (21, 22). However, the process by which *H. pylori* infection influences EBV-associated GC through an epigenetics-dependent molecular mechanism has not been previously elucidated. In this study, we investigated the relative levels of expression of DNMTs using the coinfection model system at 1, 2, and 5 dpi using NCI-N87 gastric cells, which mimic primary gastric epithelium cells. Upon coinfection with *H. pylori* and EBV, the NCI-N87 cells were highly methylated at 2 dpi, with a significant increase in expression of all DNMTs examined, and the DNMTs remained induced, except for the results seen with DNMT3L, which showed little or no detection (Fig. 5A). Further, we investigated the promoter methylation patterns of a number of TSGs (using EpiTect methyl II PCR arrays, without the need for bisulfite sequencing [SABiosciences, Frederick, MD] of the regulatory regions of the human tumor suppressor genes), as methylation impacts the oncogenic potential of the infected NCI-N87 cells. Our findings strongly demonstrated that EBV infection of NCI-N87 induced promoter methylation of a number of TSGs and




FIG 5 *H. pylori* and EBV coinfection alters the expression of host DNMTs, leading to hypermethylation of TSGs, downregulation of TSG expression, and proliferation of gastric cells. (A) Gene expression analysis of host DNA methyl transferases in response to EBV infection and *H. pylori*-EBV coinfection. After infection, cell samples were collected at different time points. qPCR analysis was performed, and relative

(Continued on next page)

that the presence of *H. pylori* further induced the level of methylation of these TSGs, which are involved in cell cycle, apoptosis, and DNA damage responses (Fig. 5B, C, and D). The hypermethylated TSGs included APC (adenomatous polyposis coli), BRCA1, FHIT, MGMT (methyl guanine DNA methyl transferase), NEUROG1, PTEN (phosphatase and tensin homologue), RUNX3, TP73, and VHL genes (Fig. 5B, C, and D). TSGs showing no change in status or decreased methylation in comparisons between the results seen with EBV infection alone and coinfection with EBV and *H. pylori* included the CDKN2A, DAPK1, GSTP1, and RASSF1 genes (Fig. 5B, C, and D). A detailed description of the genes affected by methylation reprogramming is provided in Table S1 in the supplemental material. The complete list of 22 genes and the associated functions can be found in Table S2.

We clustered the TSGs into distinct functional classes, and, from that analysis, we showed that *in vitro* infection of the NCI-N87 gastric cells by *H. pylori* and EBV was associated with transcriptional repression of a number of cell cycle genes (APC, BRCA1, CDKN2A, FHIT, NEUROG1, PTEN, RUNX3, TP73, and VHL), genes involved in apoptosis (BRCA1, CDKN2A, MGMT, PTEN, RUNX3, TP73, and VHL), and genes involved in DNA damage repair (APC, BRCA1, MGMT, and TP73) (Fig. 5B, C, and D) (Table S2).

Coinfection of gastric NCI-N87 cells with *H. pylori* and EBV led to transcription repression of TSGs through methylation of their promoter regulatory elements.

Exposure to carcinogens can change the methylation patterns of regulatory genes and results in suppression of their expression (23). To support our findings indicating that expression of DNMTs is significantly induced during coinfection of NCI-N87 gastric epithelial cells with *H. pylori* and EBV, we examined cellular genes in major functional classes (cell cycle, apoptosis, and DNA damage repair) at the transcript level. We performed quantitative PCR (qPCR) using experimental settings similar to those previously described (20). A detailed description of the genes examined, which were regulated through transcriptional reprogramming, is provided in Table S3.

The results showed that coinfection with *H. pylori* and EBV was associated with deregulation of cell cycle, apoptosis, and DNA damage repair genes (Fig. 5E, F, and G). The majority of the genes investigated showed a reduction in transcript levels, except for CDKN1 (p21), which showed increased levels, and the results are represented as a heat map (Fig. 5E, F, and G). The TP73, VHL, APC, BRCA1, and BRCA2 genes were downregulated, but the changes were not as dramatic, suggesting that a stringent balance is required for their expression in NCI-N87 gastric cells coinfecting with *H. pylori* and EBV (Fig. 5E, F, and G). Further analysis of the associated cellular pathways using Ingenuity pathway analysis supported our findings indicating that dysregulation of the TSGs is likely critical for development of gastric cancer mediated by *H. pylori* and EBV, as the majority of the genes that were dysregulated were connected to gastric cancer development (Fig. S6A).

FIG 5 Legend (Continued)

transcriptional changes are presented in the form of a heat map. Expression of individual DNMTs was normalized to the results determined for a no-infection control. The experiment was performed three times. Min, minimum; Max, maximum. (B to D) Methyl array analysis for promoter methylation profiling of TSGs of cell cycle (B), apoptosis (C), and DNA damage repair (D) pathways in response to mock infection (Mock), EBV infection, and *H. pylori*-EBV coinfection in NCI-N87 cells was performed. Relative methylation data are presented as a heat map where individual genes are normalized against mock infection. In response to large-scale methylation of genomic DNA, the expression profiles of cell cycle, apoptosis, and DNA damage repair TSGs were modulated. The levels of modulation were measured through RT-qPCR. (E to G) Relative expression levels of cell cycle (E), apoptosis (F), and DNA damage repair (G) TSGs were plotted as a heat map normalized against the results of mock infection. Expression of these TSGs was mostly dampened in the case of coinfection. (H) Using the standard trypan blue exclusion assay method, proliferation of GC cells under different conditions was scored. (I) A colony formation assay was performed using a previously described method (68) and crystal violet staining. (J) A model depicting the modulation of the cell cycle, apoptosis, and DNA damage repair pathways that can lead to tumorigenesis of EBV-*H. pylori*-positive gastric epithelial cells. *H. pylori*-promoted augmentation of DNMTs in host cells changes hypermethylation at the genome level and represses tumor suppressor gene expression and therefore function. This results in an increase in the oncogenic activities of the infected cells.

Gastric epithelial NCI-N87 cells were further exposed to *H. pylori* and EBV (along with controls) to investigate their viability and proliferative activities (Fig. 5H and I). We found that coinfection enhanced the viability of the cells as seen by trypan blue exclusion assay and increased colony formation, as would be expected for a more robust cancer phenotype (Fig. 5H and I). A model representing coinfection of the gastric mucosa and the sequence of events resulting in tumorigenesis is provided (Fig. 5J). The *H. pylori*(CagA⁻) mutant showed increases similar to those seen with infection with EBV alone (Fig. 5H and I). Importantly, the results showed that infections performed with *H. pylori*(WT) and *H. pylori*(CagA⁻) without EBV did not have any direct effect on the oncogenic phenotype or on the transcript levels of the TSGs examined, indicating that *H. pylori* can enhance the functional ability of EBV to drive oncogenesis but is limited in its own capacity to drive the oncogenic phenotype of gastric epithelial cells (Fig. S6B and C).

DISCUSSION

Oncogenesis associated with approximately 20% of human cancers is driven by infectious agents as the causative inducers (24). Epigenetic modulators alter the expression of cellular genes, which modifies the microenvironment to one suitable for oncogenesis. EBV is known to promote oncogenesis through epigenetic modifications resulting in transcription reprogramming of infected cells. These changes contribute to the development of cancers of epithelial and lymphoid origin (25, 26).

In the present study, NCI-N87 gastric epithelial cells were used; the properties of those cells closely mimic the properties of primary gastric epithelial cells based on the cell-cell interaction mechanisms, analysis of adherent junction, and expression of cytoskeleton and cell-matrix proteins (14, 15). Notably, *H. pylori* specifically targets and resides at the adherent junction (27, 28). This prompted us to examine a preferable model by which EBV infection can successfully occur in *H. pylori*-exposed NCI-N87 gastric cells. Forty-eight hours of preincubation with *H. pylori* resulted in a consistently higher EBV DNA copy number as well as in higher GFP expression with GFP-EBV-*H. pylori* coinfection. Earlier studies showed that *H. pylori* can modulate expression of a number of cellular genes associated with inflammation. Furthermore, this infection system provided a suitable niche for EBV-driven proliferation (29, 30). Our studies demonstrated that exposure of NCI-N87 to *H. pylori* prior to EBV infection significantly increased the efficiency of EBV infection and led to increased viral genome copy numbers in the gastric epithelial cells. To determine if this was unique to NCI-N87 cells, we replicated the coinfection experiment in AGS cells (representing another gastric epithelial cell line), which showed similar effects (data not shown). These results support our hypothesis that exposure to *H. pylori* can enhance the inflammatory response which facilitates signaling activities and drives EBV-mediated proliferation of gastric epithelial cells. Further, to address the possibility of passive GFP uptake or enhancement of fluorescence caused by dead cellular aggregates, we performed a passive GFP uptake assay and a time course analysis post-EBV infection. The results further validated the findings revealed by an increase in the level of GFP expression and in viral copy numbers and indicated that the increase in the GFP signal can be caused only by infection and virus replication. The HEK293T cells expressing GFP alone were treated under experimental conditions similar to those used in the EBV preparation, and culture supernatants were used for incubation with the NCI-N87 cells. The results showed that neither dead cells nor cellular debris contributed to the GFP fluorescence observed in our experimental system.

Latent and lytic genes (EBNA1 and BZLF1 genes, respectively) displayed higher expression than the control at increasing time points in our quantitative PCR and immunofluorescence analyses. This trend for EBNA1 and BZLF1 expression in coinfections performed with *H. pylori* suggests that *H. pylori* contributed to the increased efficiency of EBV infection and to early replication. This increase in GFP expression was most likely a direct consequence of increased levels of infection and viral replication

leading to increased persistent production of virus particles during the early period of infection.

Furthermore, using *H. pylori* cell-free culture supernatant, we were able to replicate the results described above. This provided strong evidence that the enhanced levels of infectivity and viral copy numbers were due to an *H. pylori*-encoded secretory factor. The higher expression of latent as well as lytic genes carried by EBV and the infection of a fresh culture of gastric epithelial cells with progeny virus suggested that the results were the consequence of increased EBV replication in the cells in the presence of *H. pylori*. Also, *H. pylori* coinfection resulted in a drop in viral copy numbers, although the drop was less than that seen with EBV alone in the presence of acyclovir (ACV), which inhibits herpesvirus replication at inhibitory concentrations (31). It should be noted that the presence of *H. pylori* can alter the microenvironment of the gastric epithelial cells and may enhance the efficiency of viral infection (32).

The cytotoxin-associated gene A (CagA) protein is a secretory antigen located on the surface of *H. pylori* secretory vesicles (32). It forms a complex with cell junction proteins, causing a morphological dysplastic alteration in epithelial cells (27). This alteration is important and contributes to the oncogenic process (33). Furthermore, CagA-positive *H. pylori* is associated with aggressive forms of disease, such as a severe form of gastritis, peptic ulcers, and GC (34–36). *H. pylori* CagA-positive strains can also alter the inflammation-driven cellular response and show increased levels of interleukin-8 (IL-8) expression (35, 37). Our results support the hypothesis that human gastric epithelial cells have enhanced susceptibility to EBV infection in the presence of the *H. pylori* wild-type strain (carrying the CagA gene). An *H. pylori* CagA mutant showed a significant reduction in the level of viral infection similar to that seen with EBV alone, suggesting that CagA was a major contributor to the increased efficiency of infection. Similar observations were made with cell-free culture supernatants of the wild-type strain and the CagA-deleted mutant, indicating that the active factor was secreted in the culture medium. Cells have more than one mechanism for CagA uptake by gastric cells. The first mechanism is that of utilizing the type IV bacterial secretion system that directly injects the CagA factor into the cells (38). Alternatively, binding of CagA to cell surface lipid phosphatidyl serine activated integrins, and rearrangement of actin leads to endocytosis of CagA or its fragments and causes phenotypic alteration in gastric epithelial cells (39). Here, our results supported the hypothesis that the alternative (second) mechanism is the one used, as the culture supernatant showed enhanced levels of EBV infection and copy numbers.

Small-molecule effectors encoded by microbial agents can drive oncogenesis. Additionally, interspecies competition and synergies between resident microbes can have a significant impact on functional outcomes. In particular, as we have observed in the context of *H. pylori* and EBV dynamics in GC, phosphorylated CagA interacts with the proto-oncogene SPH1, a host tyrosine phosphatase, and this, in turn, dampens the CagA-induced oncogenic action (38). Conversely, EBV infection leads to promoter hypermethylation of SPH1 which rescues the phosphorylated CagA from phosphatase and enhances gastric oncogenesis (38). Our results add to those results and show that TSGs are also regulated and that CagA is an important *H. pylori*-encoded factor.

Aberrant DNA methylation in GC is an important driver of the oncogenic process and is associated with both *H. pylori* infection and EBV infection (40–42). Three major classes of DNMTs, namely, DNMT class 1 (DNMT1) (involved in postreplication maintenance of the existing methylation pattern of newly synthesized strands) and DNMT3A and DNMT3B (DNMT3A/3B) (involved in the *de novo* methylation of CpGs), are important contributors to cellular and viral methylation patterns (43). Another member of the DNMT3 family, DNMT3L, is catalytically inactive but has a role in the development of germ cells (44). However, binding of DNMT3L with DNMT3A/3B increases their catalytic activity by as much as 15-fold (44). The role of DNMT2 is not completely understood; DNMT2 is possibly associated with methylation of tRNAs and has a protective function (45, 46). Empirical evidence indicates that the DNMTs encoded by the host cells, and not the *H. pylori*-encoded DNMTs, contribute to DNA methylation of the host genome

(47). Further, more-exhaustive analysis failed to detect any *H. pylori*-encoded DNMTs in the *H. pylori* secretory proteome (32). Here, we show that coinfection by *H. pylori* and EBV induced expression of the epigenetic effectors of the host cell, including DNMTs. Further, significant upregulation of DNMT3A/3B led to methylation of CpG islands of TSGs in the host genome. Notably, EBV is a known epigenetic modulator regulating a range of cellular processes important for oncogenesis (19). In this coinfection model system, we observed a drastic shift in the host epigenome. There are several high-throughput methods for methylation detection, such as bisulfite sequencing, pyrosequencing, and next-generation sequencing (48–50). However, we elected to use an EpiTect methyl II PCR array system based on the following criteria. First, it is pathway focused and rapid; second, it is reliable, reproducible, and cost-effective. Most importantly, its outcome is comparable to those obtained using other techniques, including bisulfite sequencing (51).

Upregulation of DNMTs is directly responsible for promoter hypermethylation of a broad range of tumor suppressor genes, which in turn results in decreased expression of TSGs (20). Further, in our current study, we showed that exposure of gastric epithelial cells to *H. pylori* prior to EBV infection led to promoter hypermethylation of TSGs and to downregulation of their transcription. This led to increased cell proliferation and an enhanced oncogenic phenotype as seen in our colony formation assays. These results support those of a previous study which showed that a number of TSGs had enhanced methylation patterns in gastric cells (52).

Multiple pathways and cellular processes are affected by extensive promoter methylation of TSGs. Cyclin-dependent kinase inhibitor 2A blocks MDM2-mediated degradation of p53 (53). CDKN2A interacts with MDM2 and inhibits the cytoplasm-nuclear movement of MDM2 (53). This stabilizes p53 and enhances p53-mediated apoptosis (53). CDKN2A also binds to E2F1 and Bcl6 and suppresses their transcription activity (54). Downstream targets of BCL6 are proteins involved in DNA damage sensing and cell cycle proliferation (55). CDKN1A (p21), however, was not shut down, which highlights its importance in the context of EBV-mediated oncogenesis (56). MGMT (methyl guanine DNA methyl transferase) is associated with several cancer types, including colorectal cancer, lung cancer, and glioblastoma (57). MGMT is involved in the DNA repair process, protecting against the activity of alkylating agents, and caused the alkylated guanidine to revert to its natural state by transferring an alkyl group to specific cysteine residues of MGMT (57). The APC (adenomatous polyposis coli) promoter is also known to be methylated in aggressive forms of breast cancer and other cancers (58) and serves as an inhibitor of Wnt signaling (59).

Loss of the phosphatase and tensin homologue (PTEN) is associated with many cancers and functions as a negative regulator of the PI3-kinase/AKT pathway by downregulating PIP3 (phosphatidyl inositol 3,4,5-triphosphate) levels (60). In one study on EBV-positive GC, PTEN was found to be hypermethylated (61). Upon infection with recombinant EBV, GC cell lines MKN1 and MKN7 showed DNMT1 upregulation along with hypermethylation of the regulatory region of the PTEN gene (61). This demonstrates that the association of infection, DNMT-mediated changes in methylation of the cellular genome, and dysregulation of cellular signaling was important for oncogenesis (61). Another study showed that epigenetic alterations in EBV-positive GC downregulated meiotic recombination protein Rec8 in 100% of the cases examined, thereby causing loss of its tumor-suppressive effect (62). This represents a direct mechanism by which pathogen-driven epigenetic alteration is linked to the loss of tumor suppressor function, causing tumorigenic progression (Fig. 5).

The present study demonstrated an epigenetic mechanism which specifically involved DNMT-mediated TSG silencing in infected gastric epithelial cells. It establishes the *H. pylori*-EBV nexus, which creates a tumor microenvironment suitable for gastric epithelial cell proliferation and oncogenesis. Thus, *H. pylori* exposure aids in proliferation of EBV-infected gastric epithelial cells through modulation of the cell cycle, apoptosis, and DNA damage repair pathways, leading to uncontrolled proliferation of virus-infected cells and development of gastric cancer.

MATERIALS AND METHODS

Ethics statement. All the work was performed in accordance with ethical guidelines of University of Pennsylvania and Helsinki recommendations.

Cells, virus, and bacterial cultures. The NCI-N87 and AGS human gastric epithelial cell lines were obtained from the American Type Culture Collection (ATCC); the cell lines are negative for EBV (62). As described earlier, HEK293T cells containing GFP-EBV were cultured and used for EBV amplification (63).

Induction of virus from HEK293T cells containing GFP-EBV. Cultured 293T-GFP-EBV cells were induced for 5 days with 20 ng/ml tetradecanoyl phorbol acetate (TPA) and 3 mM butyric acid (Sigma-Aldrich Corp., St. Louis, MO), and the virus was purified as described previously (64).

Infection of NCI-N87 and AGS cells with GFP-EBV and H. pylori. NCI-N87 cells were grown over poly-L-lysine-coated sterile coverslips in 6-well plates. When the cells reached 60% confluence, *H. pylori* exposure was set up using a 0.4- μ M-pore-size transwell. After 48 h, the virus was added to the culture medium.

A primary *H. pylori* culture was washed twice with sterile 1 \times phosphate-buffered saline (PBS) and suspended in serum- and antibiotic-free RPMI medium. Infection was performed in a 6-well plate using a transwell system (Corning Inc., Lowell, MA) (0.4 μ M pore size, 24-mm diameter). NCI-N87 and AGS cells were incubated with *H. pylori* for 48 h prior to the GFP-EBV treatment.

DNA and RNA extraction. DNA was isolated using a DNeasy blood and tissue kit (Qiagen, Valencia, CA) following the manufacturer's instructions. Extracellular viral DNA was extracted from culture supernatants as previously described (65), and DNA was quantified using real-time quantitative PCR (RT-qPCR) performed with previously described primers (20, 63).

Replication inhibition by ACV. Acyclovir [ACV; 9-(2-hydroxyethoxy methyl) guanine] is an antiviral. A 25 μ M concentration of ACV was used for significant and reproducible EBV replication inhibition in NCI-N87 cells (63).

Profiling of DNA methylation. DNA samples obtained after infection were analyzed using human tumor suppressor gene EpiTect DNA methylation PCR array signature panel EAHS51ZC (SABiosciences, Frederick, MD) following the manufacturer's instructions. Please refer to Text S1 in the supplemental material for a detailed description of the procedure.

Real-time quantitative PCR. Real-time quantitative PCR (RT-qPCR) analysis was carried out using previously described methods (66). Details are provided in Text S1 and elsewhere in Materials and Methods.

Cell proliferation assay. A cell proliferation assay was performed using trypan blue exclusion and crystal violet staining methods as previously described (67, 68). Brief descriptions are provided in Text S1 and elsewhere in Materials and Methods.

Statistical analysis. Data were statistically analyzed using Student's *t* test. All the results were derived from triplicate experiments (***, *P* value of <0.001 [using Student's *t* test and Graph Pad Prism version 6]).

Data availability. All of the data sets that support the findings of this study are available in the present manuscript in either the main text or the supplemental material.

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/mBio.00649-18>.

TEXT S1, DOCX file, 0.02 MB.

FIG S1, TIF file, 1.1 MB.

FIG S2, TIF file, 2.2 MB.

FIG S3, TIF file, 2.2 MB.

FIG S4, TIF file, 2.4 MB.

FIG S5, TIF file, 3.5 MB.

FIG S6, TIF file, 2.2 MB.

TABLE S1, DOCX file, 0.1 MB.

TABLE S2, DOCX file, 0.1 MB.

TABLE S3, DOCX file, 0.05 MB.

ACKNOWLEDGMENTS

We are thankful to Richard M. Peek, Vanderbilt University, Nashville, TN, for his kind gift of the HP 60190 and HP 60190 CagA⁻ strains.

This work was supported by grants R01-CA17971-01A1, R01-CA177423-01, and P01-CA174439-02 to Erle S. Robertson.

Besides acknowledging the financial support described above, we have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed.

E.S.R. and M.K.S. contributed in conceiving and designing the experiments; M.K.S.,

S.P., H.C.J., and S.K.S. performed the experiments; S.P., H.C.J., and E.S.R. analyzed the data; S.P. and E.S.R. wrote the manuscript.

REFERENCES

- IARC Monogr Eval Carcinog Risks Hum. 1994. IARC working group on the evaluation of carcinogenic risks to humans: some industrial chemicals. Lyon, 15–22 February 1994. IARC Monogr Eval Carcinog Risks Hum 60:1–560.
- IARC Monogr Eval Carcinog Risks Hum. 1994. Infection with *Helicobacter pylori*. IARC Monogr Eval Carcinog Risks Hum 61:177–240.
- Hsu JL, Glaser SL. 2000. Epstein-Barr virus-associated malignancies: epidemiologic patterns and etiologic implications. *Crit Rev Oncol Hematol* 34:27–53. [https://doi.org/10.1016/S1040-8428\(00\)00046-9](https://doi.org/10.1016/S1040-8428(00)00046-9).
- Chang MS, Kim WH. 2005. Epstein-Barr virus in human malignancy: a special reference to Epstein-Barr virus associated gastric carcinoma. *Cancer Res Treat* 37:257–267. <https://doi.org/10.4143/crt.2005.37.5.257>.
- Camargo MC, Murphy G, Koriyama C, Pfeiffer RM, Kim WH, Herrera-Goepfert R, Corvalán AH, Carrascal E, Abdirad A, Anwar M, Hao Z, Kattoor J, Yoshiwara-Wakabayashi E, Eizuru Y, Rabkin CS, Akiba S. 2011. Determinants of Epstein-Barr virus-positive gastric cancer: an international pooled analysis. *Br J Cancer* 105:38–43. <https://doi.org/10.1038/bjc.2011.215>.
- Takada K. 2000. Epstein-Barr virus and gastric carcinoma. *Mol Pathol* 53:255–261. <https://doi.org/10.1136/mp.53.5.255>.
- Gulley ML, Pulitzer DR, Eagan PA, Schneider BG. 1996. Epstein-Barr virus infection is an early event in gastric carcinogenesis and is independent of bcl-2 expression and p53 accumulation. *Hum Pathol* 27:20–27. [https://doi.org/10.1016/S0046-8177\(96\)90133-1](https://doi.org/10.1016/S0046-8177(96)90133-1).
- Imai S, Koizumi S, Sugiura M, Tokunaga M, Uemura Y, Yamamoto N, Tanaka S, Sato E, Osato T. 1994. Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. *Proc Natl Acad Sci U S A* 91:9131–9135. <https://doi.org/10.1073/pnas.91.19.9131>.
- Levine PH, Stemmermann G, Lennette ET, Hildesheim A, Shibata D, Nomura A. 1995. Elevated antibody titers to Epstein-Barr virus prior to the diagnosis of Epstein-Barr-virus-associated gastric adenocarcinoma. *Int J Cancer* 60:642–644. <https://doi.org/10.1002/ijc.2910600513>.
- Cárdenas-Mondragón MG, Carreón-Talavera R, Camorlinga-Ponce M, Gomez-Delgado A, Torres J, Fuentes-Panáná EM. 2013. Epstein-Barr virus and *Helicobacter pylori* co-infection are positively associated with severe gastritis in pediatric patients. *PLoS One* 8:e62850. <https://doi.org/10.1371/journal.pone.0062850>.
- Imai K, Ogata Y, Ochiai K. 2012. Microbial interaction of periodontopathic bacteria and Epstein-Barr virus and their implication of periodontal diseases. *J Oral Biosci* 54:164–168. <https://doi.org/10.1016/j.job.2012.07.001>.
- Niller HH, Szenthe K, Minarovits J. 2014. Epstein-Barr virus-host cell interactions: an epigenetic dialog? *Front Genet* 5:367. <https://doi.org/10.3389/fgene.2014.00367>.
- Valenzuela MA, Canales J, Corvalán AH, Quest AF. 2015. *Helicobacter pylori*-induced inflammation and epigenetic changes during gastric carcinogenesis. *World J Gastroenterol* 21:12742–12756. <https://doi.org/10.3748/wjg.v21.i45.12742>.
- Basque JR, Chénard M, Chailier P, Ménard D. 2001. Gastric cancer cell lines as models to study human digestive functions. *J Cell Biochem* 81:241–251. [https://doi.org/10.1002/1097-4644\(20010501\)81:2<241::AID-JCB1039>3.0.CO;2-B](https://doi.org/10.1002/1097-4644(20010501)81:2<241::AID-JCB1039>3.0.CO;2-B).
- Conlin VS, Curtis SB, Zhao Y, Moore EDW, Smith VC, Meloche RM, Finlay BB, Buchan AMJ. 2004. *Helicobacter pylori* infection targets adherens junction regulatory proteins and results in increased rates of migration in human gastric epithelial cells. *Infect Immun* 72:5181–5192. <https://doi.org/10.1128/IAI.72.9.5181-5192.2004>.
- Coudron PE, Kirby DF. 1989. Comparison of rapid urease tests, staining techniques, and growth on different solid media for detection of *Campylobacter pylori*. *J Clin Microbiol* 27:1527–1530.
- Murata T, Sato Y, Kimura H. 2014. Modes of infection and oncogenesis by the Epstein-Barr virus. *Rev Med Virol* 24:242–253. <https://doi.org/10.1002/rmv.1786>.
- Keates S, Keates AC, Warny M, Peek RM, Murray PG, Kelly CP. 1999. Differential activation of mitogen-activated protein kinases in AGS gastric epithelial cells by cag+ and cag- *Helicobacter pylori*. *J Immunol* 163:5552–5559.
- Kaneda N, Matsusaka K, Aburatani H, Fukayama M. 2012. Epstein-Barr virus infection as an epigenetic driver of tumorigenesis. *Cancer Res* 72:3445–3450.
- Saha A, Jha HC, Upadhyay SK, Robertson ES. 2015. Epigenetic silencing of tumor suppressor genes during in vitro Epstein-Barr virus infection. *Proc Natl Acad Sci U S A* 112:E5199–E5207. <https://doi.org/10.1073/pnas.1503806112>.
- Niller HH, Wolf H, Minarovits J. 2009. Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia. *Semin Cancer Biol* 19:158–164. <https://doi.org/10.1016/j.semcancer.2009.02.012>.
- Cancer Genome Atlas Research Network. 2014. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature* 513:202–209. <https://doi.org/10.1038/nature13480>.
- Matsusaka K, Funata S, Fukayama M, Kaneda A. 2014. DNA methylation in gastric cancer, related to *Helicobacter pylori* and Epstein-Barr virus. *World J Gastroenterol* 20:3916–3926. <https://doi.org/10.3748/wjg.v20.i14.3916>.
- McLaughlin-Drubin ME, Munger K. 2008. Viruses associated with human cancer. *Biochim Biophys Acta* 1782:127–150. <https://doi.org/10.1016/j.bbadis.2007.12.005>.
- Madou M, Zoval J, Jia G, Kido H, Kim J, Kim N. 2006. Lab on a CD. *Annu Rev Biomed Eng* 8:601–628. <https://doi.org/10.1146/annurev.bioeng.8.061505.095758>.
- Saha A, Kaul R, Murakami M, Robertson ES. 2010. Tumor viruses and cancer biology: modulating signaling pathways for therapeutic intervention. *Cancer Biol Ther* 10:961–978. <https://doi.org/10.4161/cbt.10.10.13923>.
- Amieva MR. 2003. Disruption of the epithelial apical-junctional complex by *Helicobacter pylori* CagA. *Science* 300:1430–1434.
- Hezcko U, Smith VC, Mark Meloche R, Buchan AMJ, Finlay BB. 2000. Characteristics of *Helicobacter pylori* attachment to human primary antral epithelial cells. *Microbes Infect* 2:1669–1676. [https://doi.org/10.1016/S1286-4579\(00\)01322-8](https://doi.org/10.1016/S1286-4579(00)01322-8).
- Niwa T, Tsukamoto T, Toyoda T, Mori A, Tanaka H, Maekita T, Ichinose M, Tatematsu M, Ushijima T. 2010. Inflammatory processes triggered by *Helicobacter pylori* infection cause aberrant DNA methylation in gastric epithelial cells. *Cancer Res* 70:1430–1440. <https://doi.org/10.1158/0008-5472.CAN-09-2755>.
- Sankaran-Walters S, Ransibrahmanakul K, Grishina I, Hung J, Martinez E, Prindiville T, Dandekar S. 2011. Epstein-Barr virus replication linked to B cell proliferation in inflamed areas of colonic mucosa of patients with inflammatory bowel disease. *J Clin Virol* 50:31–36. <https://doi.org/10.1016/j.jcv.2010.09.011>.
- Datta AK, Colby BM, Shaw JE, Pagano JS. 1980. Acyclovir inhibition of Epstein-Barr virus replication. *Proc Natl Acad Sci U S A* 77:5163–5166. <https://doi.org/10.1073/pnas.77.9.5163>.
- Olofsson A, Vallström A, Petzold K, Tegtmeyer N, Schleucher J, Carlsson S, Haas R, Backert S, Wai SN, Gröbner G, Arnqvist A. 2010. Biochemical and functional characterization of *Helicobacter pylori* vesicles. *Mol Microbiol* 77:1539–1555. <https://doi.org/10.1111/j.1365-2958.2010.07307.x>.
- Lax AJ. 2005. Opinion: bacterial toxins and cancer—a case to answer? *Nat Rev Microbiol* 3:343–349. <https://doi.org/10.1038/nrmicro1130>.
- Peek RM, Moss SF, Tham KT, Pérez-Pérez GI, Wang S, Miller GG, Atherton JC, Holt PR, Blaser MJ. 1997. *Helicobacter pylori* cagA+ strains and dissociation of gastric epithelial cell proliferation from apoptosis. *J Natl Cancer Inst* 89:863–868. <https://doi.org/10.1093/jnci/89.12.863>.
- Peek RM. 2001. *Helicobacter pylori* strain-specific activation of signal transduction cascades related to gastric inflammation. *Am J Physiol Gastrointest Liver Physiol* 280:G525–G530. <https://doi.org/10.1152/ajpgi.2001.280.4.G525>.
- Olivares D, Gisbert JP, Pajares JM. 2005. *Helicobacter pylori* infection and gastric mucosal epithelial cell apoptosis. *Rev Esp Enferm Dig* 97:505–520. <https://doi.org/10.4321/S1130-01082005000700006>.
- Aihara M, Tsuchimoto D, Takizawa H, Azuma A, Wakebe H, Ohmoto Y, Imagawa K, Kikuchi M, Mukaida N, Matsushima K. 1997. Mechanisms

- involved in Helicobacter pylori-induced interleukin-8 production by a gastric cancer cell line, MKN45. *Infect Immun* 65:3218–3224.
38. Saju P, Murata-Kamiya N, Hayashi T, Senda Y, Nagase L, Noda S, Matsusaka K, Funata S, Kunita A, Urabe M, Seto Y, Fukayama M, Kaneda A, Hatakeyama M. 2016. Host SHP1 phosphatase antagonizes Helicobacter pylori CagA and can be downregulated by Epstein-Barr virus. *Nat Microbiol* 1:16026. <https://doi.org/10.1038/nmicrobiol.2016.26>.
 39. Tohidpour A, Gorrell RJ, Roujeinikova A, Kwok T. 2017. The middle fragment of Helicobacter pylori CagA induces actin rearrangement and triggers its own uptake into gastric epithelial cells. *Toxins* 9:237. <https://doi.org/10.3390/toxins9080237>.
 40. Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, Iguchi M, Arie K, Kaneda A, Tsukamoto T, Tatematsu M, Tamura G, Saito D, Sugimura T, Ichinose M, Ushijima T. 2006. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. *Clin Cancer Res* 12:989–995. <https://doi.org/10.1158/1078-0432.CCR-05-2096>.
 41. Nishikawa J, Yoshiyama H, Iizasa H, Kanehiro Y, Nakamura M, Nishimura J, Saito M, Okamoto T, Sakai K, Suehiro Y, Yamasaki T, Oga A, Yanai H, Sakaida I. 2014. Epstein-Barr virus in gastric carcinoma. *Cancers* 6:2259–2274. <https://doi.org/10.3390/cancers6042259>.
 42. de Souza CR, de Oliveira KS, Ferraz JJ, Leal MF, Calcagno DQ, Seabra AD, Khayat AS, Montenegro RC, Alves APNN, Assumpção PP, Smith MC, Burbano RR. 2014. Occurrence of Helicobacter pylori and Epstein-Barr virus infection in endoscopic and gastric cancer patients from Northern Brazil. *BMC Gastroenterol* 14:179. <https://doi.org/10.1186/1471-230X-14-179>.
 43. Costello JF, Plass C. 2001. Methylation matters. *J Med Genet* 38:285–303. <https://doi.org/10.1136/jmg.38.5.285>.
 44. Gowher H, Liebert K, Hermann A, Xu G, Jeltsch A. 2005. Mechanism of stimulation of catalytic activity of Dnmt3A and Dnmt3B DNA-(cytosine-5)-methyltransferases by Dnmt3L. *J Biol Chem* 280:13341–13348. <https://doi.org/10.1074/jbc.M413412200>.
 45. Alexandrov A, Chernyakov I, Gu W, Hiley SL, Hughes TR, Grayhack EJ, Phizicky EM. 2006. Rapid tRNA decay can result from lack of nonessential modifications. *Mol Cell* 21:87–96. <https://doi.org/10.1016/j.molcel.2005.10.036>.
 46. Schaefer M, Pollex T, Hanna K, Tuorto F, Meusburger M, Helm M, Lyko F. 2010. RNA methylation by Dnmt2 protects transfer RNAs against stress-induced cleavage. *Genes Dev* 24:1590–1595. <https://doi.org/10.1101/gad.586710>.
 47. Sitaraman R. 2014. Helicobacter pylori DNA methyltransferases and the epigenetic field effect in cancerization. *Front Microbiol* 5:115. <https://doi.org/10.3389/fmicb.2014.00115>.
 48. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, Paul CL. 1992. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. *Proc Natl Acad Sci U S A* 89:1827–1831. <https://doi.org/10.1073/pnas.89.5.1827>.
 49. Shames DS, Minna JD, Gazdar AF. 2007. Methods for detecting DNA methylation in tumors: from bench to bedside. *Cancer Lett* 251:187–198. <https://doi.org/10.1016/j.canlet.2006.10.014>.
 50. Taylor KH, Kramer RS, Davis JW, Guo J, Duff DJ, Xu D, Caldwell CW, Shi H. 2007. Ultradeep bisulfite sequencing analysis of DNA methylation patterns in multiple gene promoters by 454 sequencing. *Cancer Res* 67:8511–8518. <https://doi.org/10.1158/0008-5472.CAN-07-1016>.
 51. Jiang Q, Liu C, Gu X, Wilt G, Shaffer J. 2012. EpiTect methyl II PCR array system: a simple tool for screening regional DNA methylation of a large number of genes or samples without bisulfite conversion. Qiagen, Valencia, CA. Accessed 11 1 2018.
 52. Zhao J, Liang Q, Cheung K-F, Kang W, Lung RWM, Tong JHM, To KF, Sung JY, Yu J. 2013. Genome-wide identification of Epstein-Barr virus-driven promoter methylation profiles of human genes in gastric cancer cells. *Cancer* 119:304–312. <https://doi.org/10.1002/cncr.27724>.
 53. Møller MB, Ino Y, Gerdes AM, Skjødtt K, Louis DN, Pedersen NT. 1999. Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma. *Leukemia* 13:453–459. <https://doi.org/10.1038/sj.leu.2401315>.
 54. Devgan V, Mammucari C, Millar SE, Brisken C, Dotto GP. 2005. p21WAF1/Cip1 is a negative transcriptional regulator of Wnt4 expression downstream of Notch1 activation. *Genes Dev* 19:1485–1495. <https://doi.org/10.1101/gad.341405>.
 55. Cardenas MG, Oswald E, Yu W, Xue F, MacKerell AD, Melnick AM. 2017. The expanding role of the BCL6 oncoprotein as a cancer therapeutic target. *Clin Cancer Res* 23:885–893. <https://doi.org/10.1158/1078-0432.CCR-16-2071>.
 56. Fukuda M, Kurosaki W, Yanagihara K, Kuratsune H, Sairenji T. 2002. A mechanism in Epstein-Barr virus oncogenesis: inhibition of transforming growth factor- β 1-mediated induction of MAPK/p21 by LMP1. *Virology* 302:310–320. <https://doi.org/10.1006/viro.2002.1619>.
 57. Sharma S, Salehi F, Scheithauer BW, Rotondo F, Syro LV, Kovacs K. 2009. Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis. *Anticancer Res* 29:3759–3768.
 58. Debouki-Joudi S, Trifa F, Khabir A, Sellami-Boudawara T, Frikha M, Daoud J, Mokdad-Gargouri R. 2017. CpG methylation of APC promoter 1A in sporadic and familial breast cancer patients. *Cancer Biomark* 18:133–141. <https://doi.org/10.3233/CBM-160005>.
 59. Anastas JN, Moon RT. 2013. WNT signalling pathways as therapeutic targets in cancer. *Nat Rev Cancer* 13:11–26. <https://doi.org/10.1038/nrc3419>.
 60. Vazquez F, Devreotes P. 2006. Regulation of PTEN function as a PIP3 gatekeeper through membrane interaction. *Cell Cycle* 5:1523–1527. <https://doi.org/10.4161/cc.5.14.3005>.
 61. Hino R, Uozaki H, Murakami N, Ushiku T, Shinozaki A, Ishikawa S, Morikawa T, Nakaya T, Sakatani T, Takada K, Fukayama M. 2009. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. *Cancer Res* 69:2766–2774. <https://doi.org/10.1158/0008-5472.CAN-08-3070>.
 62. Yu J, Liang Q, Wang J, Wang K, Gao J, Zhang J, Zeng Y, Chiu PWY, Ng EKW, Sung JY. 2017. REC8 functions as a tumor suppressor and is epigenetically downregulated in gastric cancer, especially in EBV-positive subtype. *Oncogene* 36:182–193. <https://doi.org/10.1038/ncr.2016.187>.
 63. Halder S, Murakami M, Verma SC, Kumar P, Yi F, Robertson ES. 2009. Early events associated with infection of Epstein-Barr virus infection of primary B-cells. *PLoS One* 4:e7214. <https://doi.org/10.1371/journal.pone.0007214>.
 64. Shukla SK, Jha HC, El-Naccache DW, Robertson ES. 2016. An EBV recombinant deleted for residues 130–159 in EBNA3C can deregulate p53/Mdm2 and cyclin D1/CDK6 which results in apoptosis and reduced cell proliferation. *Oncotarget* 7:18116–18134. <https://doi.org/10.18632/oncotarget.7502>.
 65. Lu J, Verma SC, Cai Q, Robertson ES. 2011. The single RBP-Jkappa site within the LANA promoter is crucial for establishing Kaposi's sarcoma-associated herpesvirus latency during primary infection. *J Virol* 85:6148–6161. <https://doi.org/10.1128/JVI.02608-10>.
 66. Saha A, Murakami M, Kumar P, Bajaj B, Sims K, Robertson ES. 2009. Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2. *J Virol* 83:4652–4669. <https://doi.org/10.1128/JVI.02408-08>.
 67. Banerjee S, Lu J, Cai Q, Sun Z, Jha HC, Robertson ES. 2014. EBNA3C augments Pim-1 mediated phosphorylation and degradation of p21 to promote B-cell proliferation. *PLoS Pathog* 10:e1004304. <https://doi.org/10.1371/journal.ppat.1004304>.
 68. Jha HC, Sun Z, Upadhyay SK, El-Naccache DW, Singh RK, Sahu SK, Robertson ES. 2016. KSHV-mediated regulation of Par3 and SNAIL contributes to B-cell proliferation. *PLoS Pathog* 12:e1005801. <https://doi.org/10.1371/journal.ppat.1005801>.